• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

In midst of Epipen shortage, Kaleo confirms ‘sufficient supply’ of Auvi-Q auto-injectors

August 14, 2018 By Sarah Faulkner

KaleoKaleo said today that despite ongoing manufacturing delays reported by epinephrine auto-injector manufacturers, Kaleo’s Auvi-Q device is available via prescription and that the privately-held company has ‘sufficient supply to meet any anticipated demand.’

Kaleo’s epinephrine auto-injector features voice instructions that guide users through the drug-delivery process and an auto-retractable needle system, according to the company.

“We understand how critically important it is for those affected by life-threatening allergies to be able to access an epinephrine auto-injector, especially as families prepare for the back to school season. Kaléo is able to fill, and is filling, all the Auvi-Q orders through our direct delivery service at www.auvi-q.com,” Phil Rackliffe, GM of Kaleo’s allergy & pediatrics unit, said in prepared remarks. “It’s important to note that patients must obtain Auvi-Q through the direct delivery service to ensure delivery to their home or healthcare provider’s office and the best expiration dating for Auvi-Q.”

Earlier this year, a survey from the advocacy group Food Allergy Research & Education found that hundreds of people across the U.S. have had trouble getting an Epipen.

Mylan (NSDQ:MYL), which distributes the emergency allergy auto-injector, reportedly told the FDA months ago that manufacturing delays experienced by its partner, Pfizer’s Meridian Medical Technologies, were straining its Epipen supply.

Several epinephrine auto-injector manufacturers have reported shortages, according to the U.S. regulatory agency’s website, including Impax Laboratories (NSDQ:IPXL), Mylan and Hospira.

Updated 8/14 to reflect that Mylan does not make the Epipen device. 

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory Tagged With: Hospira Inc., Impax Laboratories, Kaleo Inc, Mylan

IN CASE YOU MISSED IT

  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS